Omeros Corporation completed an asset purchase agreement with Novo Nordisk on November 25, 2025, receiving $240 million upfront and potential future payments totaling $2.1 billion related to developing a new treatment, zaltenibart. The company also repaid $72.6 million of debt using part of this upfront payment.